WO2015016523A1 - 소분자 화합물을 포함하는 만능성 줄기세포의 염색체 안정성 유지용 조성물 - Google Patents
소분자 화합물을 포함하는 만능성 줄기세포의 염색체 안정성 유지용 조성물 Download PDFInfo
- Publication number
- WO2015016523A1 WO2015016523A1 PCT/KR2014/006642 KR2014006642W WO2015016523A1 WO 2015016523 A1 WO2015016523 A1 WO 2015016523A1 KR 2014006642 W KR2014006642 W KR 2014006642W WO 2015016523 A1 WO2015016523 A1 WO 2015016523A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stem cells
- composition
- cells
- small molecule
- inhibitor
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 145
- -1 small-molecule compound Chemical class 0.000 title claims abstract description 87
- 208000037051 Chromosomal Instability Diseases 0.000 title claims abstract description 20
- 210000001778 pluripotent stem cell Anatomy 0.000 title abstract description 17
- 239000003112 inhibitor Substances 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 30
- 230000005778 DNA damage Effects 0.000 claims abstract description 27
- 231100000277 DNA damage Toxicity 0.000 claims abstract description 27
- 210000000349 chromosome Anatomy 0.000 claims abstract description 21
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 17
- 230000035772 mutation Effects 0.000 claims abstract description 17
- 239000011435 rock Substances 0.000 claims abstract description 17
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 10
- 230000001939 inductive effect Effects 0.000 claims abstract description 9
- 238000012258 culturing Methods 0.000 claims abstract description 8
- 210000000130 stem cell Anatomy 0.000 claims description 156
- 210000004027 cell Anatomy 0.000 claims description 101
- 230000004069 differentiation Effects 0.000 claims description 72
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 230000002441 reversible effect Effects 0.000 claims description 26
- 102000014172 Transforming Growth Factor-beta Type I Receptor Human genes 0.000 claims description 19
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 claims description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- 235000006708 antioxidants Nutrition 0.000 claims description 15
- 230000006698 induction Effects 0.000 claims description 15
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims description 12
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 claims description 12
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 11
- 229960005070 ascorbic acid Drugs 0.000 claims description 9
- 101100239628 Danio rerio myca gene Proteins 0.000 claims description 8
- 239000002211 L-ascorbic acid Substances 0.000 claims description 7
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 7
- 210000001082 somatic cell Anatomy 0.000 claims description 7
- 102000043136 MAP kinase family Human genes 0.000 claims description 6
- 108091054455 MAP kinase family Proteins 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- DOBKQCZBPPCLEG-UHFFFAOYSA-N n-benzyl-2-(pyrimidin-4-ylamino)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(NC=2N=CN=CC=2)=NC=1C(=O)NCC1=CC=CC=C1 DOBKQCZBPPCLEG-UHFFFAOYSA-N 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 4
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 4
- DVEXZJFMOKTQEZ-JYFOCSDGSA-N U0126 Chemical compound C=1C=CC=C(N)C=1SC(\N)=C(/C#N)\C(\C#N)=C(/N)SC1=CC=CC=C1N DVEXZJFMOKTQEZ-JYFOCSDGSA-N 0.000 claims description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 4
- HCZKYJDFEPMADG-UHFFFAOYSA-N nordihydroguaiaretic acid Chemical compound C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims description 3
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 claims description 3
- 229930003935 flavonoid Natural products 0.000 claims description 3
- 150000002215 flavonoids Chemical class 0.000 claims description 3
- 235000017173 flavonoids Nutrition 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 102000000568 rho-Associated Kinases Human genes 0.000 claims description 3
- 108010041788 rho-Associated Kinases Proteins 0.000 claims description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 2
- SLYRGJDSFOCAAI-UHFFFAOYSA-N 1,3-thiazolidin-2-one Chemical compound O=C1NCCS1 SLYRGJDSFOCAAI-UHFFFAOYSA-N 0.000 claims description 2
- GBOKNHVRVRMECW-UHFFFAOYSA-N 1-pyridin-4-yl-3-(2,4,6-trichlorophenyl)urea Chemical compound ClC1=CC(Cl)=CC(Cl)=C1NC(=O)NC1=CC=NC=C1 GBOKNHVRVRMECW-UHFFFAOYSA-N 0.000 claims description 2
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 claims description 2
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 claims description 2
- 235000007034 Carum copticum Nutrition 0.000 claims description 2
- 102000016938 Catalase Human genes 0.000 claims description 2
- 108010053835 Catalase Proteins 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 2
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 claims description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229960001799 aurothioglucose Drugs 0.000 claims description 2
- 235000013734 beta-carotene Nutrition 0.000 claims description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 2
- 239000011648 beta-carotene Substances 0.000 claims description 2
- 229960002747 betacarotene Drugs 0.000 claims description 2
- 235000005487 catechin Nutrition 0.000 claims description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 2
- 229950001002 cianidanol Drugs 0.000 claims description 2
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 claims description 2
- 229940074391 gallic acid Drugs 0.000 claims description 2
- 235000004515 gallic acid Nutrition 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 239000002516 radical scavenger Substances 0.000 claims description 2
- 235000021283 resveratrol Nutrition 0.000 claims description 2
- 229940016667 resveratrol Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims 2
- FSILHPZFNRDTOR-RZVRUWJTSA-N (2R)-2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)N[C@@H](CS)C(O)=O.CC(=O)N[C@@H](CS)C(O)=O FSILHPZFNRDTOR-RZVRUWJTSA-N 0.000 claims 1
- 235000001258 Cinchona calisaya Nutrition 0.000 claims 1
- 240000004984 Trachyspermum ammi Species 0.000 claims 1
- TUCIXUDAQRPDCG-UHFFFAOYSA-N benzene-1,2-diol Chemical compound OC1=CC=CC=C1O.OC1=CC=CC=C1O TUCIXUDAQRPDCG-UHFFFAOYSA-N 0.000 claims 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 229960000948 quinine Drugs 0.000 claims 1
- 102000029751 selenium binding Human genes 0.000 claims 1
- 108091022876 selenium binding Proteins 0.000 claims 1
- 229940124647 MEK inhibitor Drugs 0.000 abstract description 15
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 12
- 230000032459 dedifferentiation Effects 0.000 abstract description 11
- 210000004263 induced pluripotent stem cell Anatomy 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 description 17
- 210000001671 embryonic stem cell Anatomy 0.000 description 16
- 206010043276 Teratoma Diseases 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 230000007774 longterm Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 210000003981 ectoderm Anatomy 0.000 description 8
- 238000012423 maintenance Methods 0.000 description 8
- 241001430294 unidentified retrovirus Species 0.000 description 8
- 206010061765 Chromosomal mutation Diseases 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000003125 immunofluorescent labeling Methods 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 210000001900 endoderm Anatomy 0.000 description 6
- 210000003716 mesoderm Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000001654 germ layer Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000008672 reprogramming Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000038624 GSKs Human genes 0.000 description 2
- 239000006147 Glasgow's Minimal Essential Medium Substances 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101710150336 Protein Rex Proteins 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000012757 fluorescence staining Methods 0.000 description 2
- 239000006481 glucose medium Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000013028 medium composition Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000013630 prepared media Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- LLJRXVHJOJRCSM-UHFFFAOYSA-N 3-pyridin-4-yl-1H-indole Chemical compound C=1NC2=CC=CC=C2C=1C1=CC=NC=C1 LLJRXVHJOJRCSM-UHFFFAOYSA-N 0.000 description 1
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 244000302413 Carum copticum Species 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101100478277 Homo sapiens SPTA1 gene Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 description 1
- 101100537302 Mus musculus Itfg1 gene Proteins 0.000 description 1
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 description 1
- 101100107167 Mus musculus Znf296 gene Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102100037608 Spectrin alpha chain, erythrocytic 1 Human genes 0.000 description 1
- 239000012163 TRI reagent Substances 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009391 cell specific gene expression Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
Definitions
- the present invention relates to a composition for maintaining chromosomal stability of pluripotent stem cells comprising a small molecule compound, and more particularly, to the induction step and induction process of induced pluripotent stem cells,
- the present invention relates to a composition for maintaining chromosome stability of pluripotent retrodifferentiated stem cells comprising a ROCK inhibitor, a MEK inhibitor, an ALK5 inhibitor or an antioxidant capable of inhibiting numerical mutation or DNA damage.
- De-differentiated stem cell manufacturing technology is a technique for producing cells in a state similar to embryonic stem cells by using animal somatic cells, and introduced four known de-differentiation factors (Oct4, Klf4, Sox2, cMyc) into a cell and specific culture conditions. Cultivation is carried out.
- the dedifferentiated stem cells made in this way have the advantage of being able to differentiate into all tissue-specific cells and thus can be used as a material for cell therapy without ethical problems, but the production efficiency is very low, It is also difficult to guarantee safety and has the disadvantage that it is not completely similar to embryonic stem cells.
- Korean Patent Registration No. 10-1211610 uses Bmi1, a MEK inhibitor, and a GSK inhibitor to induce differentiation from somatic cells into embryonic stem cell-like cells and embryonic stem using the same.
- a method for producing cell-like cells is disclosed, and
- Korean Patent No. 10-1211624 discloses the differentiation of somatic cells into embryonic stem cell-like cells using Shh, FGFR tyrosine kinase inhibitor, MEK inhibitor and GSK inhibitor.
- compositions and methods for producing embryonic stem cell-like cells using the same are disclosed.
- Republic of Korea Patent Publication No. 10-2010-0101764 (2010.09.20.) Republic of Korea Patent Publication No.
- composition treatment improves the efficiency of retrodifferentiated stem cells, but little is known about whether such composition treatment can inhibit mutations in retrodifferentiated stem cells.
- a composition comprising a MEK inhibitor, an ALK5 inhibitor, a ROCK inhibitor, and an antioxidant can suppress mutations or DNA damage, which is one of the problems of de-differentiated stem cell production, and thus provide a stable de-differentiated stem cell. There is no bar.
- the present inventors have found that a composition containing the ROCK inhibitor Tiazovivin, the MEK inhibitor PD0325901, the ALK5 inhibitor SB431542 or the antioxidant L-ascorbic acid inhibits the structural, numerical mutations or DNA damage of dedifferentiated stem cells. It was confirmed that stability was maintained and the present invention was completed.
- Patent Document 2 Republic of Korea Patent Registration 10-1211624 (2012.12.06)
- Patent Document 3 Republic of Korea Patent Publication No. 10-2010-0101764 (2010.09.20.)
- Patent Document 4 Republic of Korea Patent Publication No. 10-2011-0094348 (2011.08.23.)
- Patent Document 5 Republic of Korea Patent Publication No. 10-2012-0094488 (2012.08.24.)
- Patent Document 6 Republic of Korea Patent Publication No. 10-2012-0121084 (2012.11.05.)
- Non-Patent Document 1 Li, W., Wei, W., Zhu, S., Zhu, J., Shi, Y., Lin, T., Hao, E., Hayek, A., Deng, H. and Ding, S. (2009a). Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 4, 16-19.
- Non-Patent Document 2 Li, W., Zhou, H., Abujarour, R., Zhu, S., Young Joo, J., Lin, T., Hao, E., Scholer, HR, Hayek, A. and Ding, S. (2009b). Generation of human-induced pluripotent stem cells in the absence of exogenous Sox 2. Stem Cells 27, 2992-3000.
- Non-Patent Document 3 Lin, T., Ambasudhan, R., Yuan, X., Li, W., Hilcove, S., Abujarour, R., Lin, X., Hahm, HS, Hao, E., Hayek, A., et al. (2009). A chemical platform for improved induction of human iPSCs. Nat Methods 6, 805-808.
- Non-Patent Document 4 Yuan, X., Wan, H., Zhao, X., Zhu, S., Zhou, Q., and Ding, S. (2011). Combined Chemical Treatment Enables Oct4-Induced Reprogramming from Mouse Embryonic Fibroblasts. Stem Cells.
- Non-Patent Document 5 Zhu, S., Li, W., Zhou, H., Wei, W., Ambasudhan, R., Lin, T., Kim, J., Zhang, K., and Ding, S (2010). Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell 7, 651-655.
- An object of the present invention is to provide a composition for maintaining chromosome stability of dedifferentiated stem cells containing at least one small molecule compound selected from the group consisting of a ROCK inhibitor, a MEK inhibitor, an ALK5 inhibitor and an antioxidant as an active ingredient.
- Another object of the present invention is to provide a method and culture method for maintaining chromosome stability of dedifferentiated stem cells, characterized in that the dedifferentiated stem cells are treated with the composition.
- Figure 1a is a diagram schematically showing the overall experimental design in the method of producing a differentiated stem cells.
- Figure 1b is a photograph of the formation of a typical form of dedifferentiated stem cells when treated with a composition comprising a small molecule compound and not treated.
- Figure 1c is a graph analyzed by comparing the production efficiency and speed of the non-differentiated stem cells not treated with the composition containing the small molecule compound and the reverse differentiated stem cells treated with the composition.
- Figures 2a and 2b is a photograph comparing the expression of pluripotent genes and proteins of pluripotent stem cells using a composition comprising a small molecule compound and pluripotent stem cells without a composition using RT-PCR and fluorescence staining .
- Figure 3a is a photograph showing the blast differentiation after the differentiation of the trioderm differentiation ability of the back-differentiated stem cells using the composition comprising a small molecule compound and the back-differentiated stem cells without the composition.
- Figure 3b shows the formation of tumors through teratoma (teratoma) formation experiments using immunodeficient mice in differentiation ability in vivo of dedifferentiated stem cells using a composition comprising a small molecule compound and dedifferentiated stem cells without a composition It is a photograph confirming the trioderm differentiation ability through histological examination.
- Figure 4a is a photograph confirming that the differentiation stem cells using a composition comprising a small molecule compound can be maintained more stable without causing unintentional differentiation when cultured without supporting cells.
- 4b and 4c are graphs confirming the increase in the proliferative capacity of pluripotent stem cells and the expression level of pluripotent genes using the composition containing the small molecule compound through cell number measurement and PCR.
- 5a to 5d is a cell number measurement through fluorescence staining of dedifferentiated stem cells using a composition comprising a small molecule compound and dedifferentiated stem cells without a composition, the size of tumors formed in vivo in immunodeficient mice In comparison, it was confirmed that the differentiation ability is improved by comparing the ability to form an EB (embryonic body).
- Figure 6a is a composition containing a small molecule compound for a long time incubated dedifferentiated stem cells (miPSC (+)), after induction of differentiation, after the addition of the composition in the initial culture step, the subdifferentiation without using the composition in the passage process Comparing the frequency of occurrence of chromosomal abnormalities in stem cells (miPSC ( ⁇ )) and dedifferentiated stem cells (miPSC ( ⁇ )) that did not use the composition at all, suggesting that compositions containing small molecule compounds prevent structural abnormalities of chromosomes. This is a confirmed chart.
- Figure 6b and 6c is a composition containing a small molecule compound in the long-term culture of dedifferentiated stem cells (miPSC (+)), induction of differentiation after the addition of the composition in the initial culture step without using the composition in the passage process
- the composition containing the small molecule compound was analyzed by analyzing representative representative phenotypes showing the numerical abnormalities and structural abnormalities of chromosomes in the reverse differentiated stem cells (miPSC ( ⁇ )) and in the reverse differentiated stem cells (miPSC ( ⁇ )) where no composition was used. This is to confirm that the numerical abnormality and structural abnormality of the is prevented.
- Figure 6d is a reversed differentiation stem cells (miPSC (+)) cultured for a long time with a composition containing a small molecule compound, induction of reverse differentiation, after the addition of the composition in the initial culture step, without the use of the composition during subculture Comparing the whole karyotype in stem cells (miPSC ( ⁇ )) and dedifferentiated stem cells (miPSC (-)) using no composition at all, the results confirmed that the composition containing the small molecule compound prevents the abnormality of the chromosome.
- FIG. 7A and 7B illustrate p1 and p30 of reverse differentiated stem cells (miPSC (+)) prepared using a composition comprising a small molecule compound, and p1 of reverse differentiated stem cells (miPSC ( ⁇ )) without using any composition.
- ⁇ H2AX protein a marker of DNA damage at p30, was analyzed to compare DNA damage protection.
- Figure 7c and 7d is the initial 7 after the induction of the reverse differentiation of the back-differentiated stem cells (miPSC (+)) prepared using a composition containing a small molecule compound and the back-differentiated stem cells (miPSC (-)) using no composition at all
- 7E and 7F show initial 5 after induction of reverse differentiation under conditions using all combinations of small molecule compounds of the present invention (SPTA), conditions for treating each of the small molecule compounds, and other small molecule compounds known to improve reverse differentiation efficiency.
- SPTA small molecule compounds of the present invention
- the present invention relates to a composition for maintaining chromosome stability of dedifferentiated stem cells containing at least one small molecule compound selected from the group consisting of a ROCK inhibitor, a MEK inhibitor, an ALK5 inhibitor and an antioxidant as an active ingredient.
- the ROCK (Rho-associated kinase) inhibitor serves to improve the stability of the chromosome, Thiazovivin, Y-27632, HA-1077 (Pasudil), HA-1100 (hydroxypasudil), H- 1152, 3- (4-pyridyl) -1H-indole, N- (4-pyridyl) -N '-(2,4,6-trichlorophenyl) urea, aurothioglucose, LY294002 and the like
- the ROCK inhibitor is most preferably Thiazovivin.
- the mitogen-activated protein kinase (MEK) inhibitor plays a role of inducing rapid reverse differentiation to improve chromosome stability, and PD0325901 or U0126 (1,4-diamino-2,3-dicyano-1,4- bis [2-aminophenylthio] butadiene), more preferably PD0325901.
- the present invention is not limited thereto, and signaling inhibitors may be used in addition to the compound to inhibit metabolic processes or inhibit expression of all MEKs.
- the ALK5 (Activin Receptor-Like Kinase-5) inhibitor serves to induce rapid reverse differentiation and improve chromosome stability, preferably A-83-01 or SB431542, more preferably SB431542.
- the present invention is not limited thereto.
- signaling inhibitors that inhibit the metabolic process or inhibit the expression of all ALK5 may be used.
- the antioxidant is not particularly limited in its kind, but is preferably vitamin E, A, C, etc., Oxothiazolidine, N-acetylcysteine, TEMPO, superoxide dismutase (SOD), glutathione peroxidase, scavenger Oxygen, hydrogen peroxide, lipooxide radicals, hydroxy radicals, metal-binding proteins, selenium, reduced glutathione, beta-carotene, flavonoids (flavonoids), Sesamol (sesamol), Gallic Acid (ajowan), Oryzanol (Orizanol), resveratrol, catechin, lecithin (lecithin), cephalin (separin), sulfhydrls (SRH), citric acid, ascorbic acid, catalase, BHA, BHT, PG, NDGA, hydroquinone, catechol and DPPD (N , Ndiphenyl-pp-phenylene-di
- Small molecule compounds of the compositions of the present invention may be prepared by artificial synthesis, and commercially prepared products may also be used. Commercially prepared products are preferably used by adding them to the medium dissolved in DMSO, in a specific embodiment of the present invention was used in addition to the DMEM medium.
- the stem cells are preferably pluripotent dedifferentiated stem cells induced by one or more genes selected from the group consisting of Oct4, Klf4, Sox2 and cMyc.
- the present invention is characterized by maintaining the stability of the chromosome through the inhibition of structural and numerical mutations or DNA damage of the chromosome.
- pluripotent or “pluripotent” is to be differentiated into cell types that collectively represent characteristics related to the cell lineage belonging to all three germ layers (endoderm, mesoderm, and ectoderm) under conditions that induce natural differentiation. It means the ability to Pluripotent stem cells or dedifferentiated stem cells can produce many or all tissues of an adult animal.
- standard tests generally accepted in the art such as tests on the ability to form teratoma in 5-10 week old SCID mice, can be used to demonstrate pluripotency of cell populations, Identification of various pluripotent stem cell specific gene expressions can also be used to detect pluripotent cells.
- Cell pluripotency can form cells of all three germ layers, from fully pluripotent cells capable of properly forming all cells of the embryo, such as embryonic stem cells and dedifferentiated stem cells. It is a continuum that extends to incomplete or partially pluripotent cells, which may not exhibit all of the characteristics of a fully pluripotent cell, such as, for example, gonad transmission or the ability to produce whole organisms. In the examples, expression of pluripotency genes or pluripotency markers as discussed elsewhere herein can be used to assess pluripotency of cells.
- pluripotent stem cell refers to a cell having the characteristics of pluripotent stem cells, and refers to pluripotent dedifferentiated stem cells, induced pluripotent stem cells, embryonic stem cells, and the like. Sex retrodifferentiated stem cells.
- characteristic of pluripotent stem cells means the characteristics of cells that distinguish pluripotent stem cells from other cells.
- Pluripotent stem cells are characterized by the ability to differentiate into cell types collectively representing the characteristics associated with cell lineages corresponding to all three types of germ layers (endoderm, mesoderm, and ectoderm) under conditions that induce differentiation.
- Mouse pluripotent stem cells express at least some, and optionally all of, markers such as SSEA1, Oct4, Klf4, Sox2, Rex1, and Nanog. Cell types associated with pluripotent stem cells also characterize pluripotent stem cells.
- dedifferentiation factor (Oct4) to the fibroblasts (tail tip fibroblast) extracted from the tail of the mouse , Klf4, Sox2, cMyc was used to prepare retrodifferentiated stem cells using retroviruses.
- the population of dedifferentiated stem cells between the cell population (miPSC (+)) cultured with the addition of the composition containing the small molecule compound and the cell population (miPSC (-)) cultured in the absence of the composition containing the small molecule compound (miPSC (+)) cultured with the addition of the composition containing the small molecule compound and the cell population (miPSC (-)) cultured in the absence of the composition containing the small molecule compound (miPSC (-)) cultured in the absence of the composition containing the small molecule compound (miPSC (-)) cultured in the absence of the composition containing the small molecule compound (miPSC (-)) cultured in the absence of the composition containing the small molecule compound).
- the rate of retrodifferentiation and the efficiency were confirmed by comparing the number of colony) and the number of colony.
- the rate of reverse differentiation was improved under the conditions using the composition containing the small molecule compound, and it was confirmed that the production efficiency was also improved as
- De-differentiated stem cells prepared using the composition comprising a small molecule compound according to the present invention is characterized in that the proliferative capacity and pluripotency maintenance ability are closer to embryonic stem cells.
- the proliferative capacity and pluripotency maintenance ability are closer to embryonic stem cells.
- expression levels of genes such as nanog, Klf4, and Zfp296, which are pluripotency genes expressed in embryonic stem cells, were improved. It was.
- the dedifferentiated stem cells prepared using the composition comprising the small molecule compound according to the present invention was confirmed that the differentiation ability is closer to the embryonic stem cells, the ectoderm differentiation ability with the neuron specific expression protein Tuj1, muscle
- the mesoderm differentiation capacity was confirmed with Desmin, a cell-specific expression protein, and endoderm differentiation capacity was identified with AFP, a cell-specific expression protein, respectively.
- the dedifferentiated stem cells using the composition of the present invention form functional neurons with higher efficiency in inducing differentiation into functional neurons.
- composition comprising the small molecule compound of the present invention is characterized by being capable of suppressing the numerical and structural mutations of the cell chromosome due to the rapid cell state change during the production of dedifferentiated stem cells.
- Chromosome karyotype analysis showed various structural chromosomal variations such as duplication, deletion, and translocation in non-differentiated stem cells that did not use the composition, but structural variants of chromosomes were not found in dedifferentiated stem cells using compositions containing small molecule compounds. was confirmed.
- the composition comprising the small molecule compound of the present invention is characterized in that it is possible to inhibit the damage of cellular DNA due to the rapid cell state change during the production of dedifferentiated stem cells.
- the immunofluorescent staining of ⁇ H2AX protein resulted in DNA damage in up to 20% of the cells in the undifferentiated stem cells without the composition, but similar to normal cells in the dedifferentiated stem cells using the composition containing small molecule compounds. DNA damage was seen only in cells of less than%.
- the small molecule compounds used in the present invention can inhibit DNA damage even when used alone, and the other small molecule compounds known to increase the reverse differentiation efficiency did not show such DNA damage inhibitory effect.
- chromosomal mutation or DNA damage as described above decreases the efficiency of cell maintenance and differentiation and induces abnormal differentiation, there is a potential risk of developing cancer cells. It can be said that it is also suitable for the purpose of cell production.
- the composition comprising the small molecule compound according to the present invention can prevent the mutation or DNA damage of the cell chromosome due to the rapid cell state change of the reverse differentiation process. In addition, it induces the rapid differentiation of somatic cells to occur faster, improves the efficiency of reverse differentiation, and improves the expression level of genes expressing embryonic stem cells specifically. Therefore, according to the present invention, it is possible to provide a pluripotent dedifferentiated stem cell having properties similar to embryonic stem cells in terms of proliferative capacity and differentiation capacity.
- composition including a small molecule compound capable of increasing the stability of the chromosome of the present invention improves safety in addition to the efficiency enhancing effect when the retrodifferentiated stem cells are used in clinical procedures.
- a composition including a small molecule compound capable of increasing the stability of the chromosome of the present invention improves safety in addition to the efficiency enhancing effect when the retrodifferentiated stem cells are used in clinical procedures.
- it is highly useful as a material for chromosomal mutation research.
- the present invention provides a method for treating dedifferentiated stem cells with a composition for maintaining chromosome stability of dedifferentiated stem cells containing at least one small molecule compound selected from the group consisting of a ROCK inhibitor, a MEK inhibitor, an ALK5 inhibitor and an antioxidant as an active ingredient.
- the present invention relates to a method for maintaining chromosome stability of dedifferentiated stem cells.
- the composition is preferably added to the initial stage of inducing the differentiation of somatic cells, the initial stage is cultured after the introduction of one or more genes selected from the group consisting of Oct4, Klf4, Sox2 and cMyc colonies are formed
- the composition is most preferably added within 4 days after the introduction of the gene, which is the initial stage of inducing reverse differentiation.
- the composition is preferably added to the long-term culture step of maintaining the differentiated stem cells formed after induction of differentiation.
- the composition may use a MEK inhibitor, an ALK5 inhibitor, a ROCK inhibitor, and an antioxidant, respectively, preferably in combination, and most preferably in combination.
- the present invention provides a method for culturing retrodifferentiated stem cells with a composition for maintaining chromosome stability of dedifferentiated stem cells containing at least one small molecule compound selected from the group consisting of a ROCK inhibitor, a MEK inhibitor, an ALK5 inhibitor, and an antioxidant as an active ingredient.
- the present invention relates to a method for culturing dedifferentiated stem cells.
- the method may further include a step performed under feeder cell-free conditions.
- stem cells When the stem cells are stabilized, they can be cultured on a gelatin-coated culture plate without supporting cells. When cultured in the absence of support cells, unnecessary differentiation occurs under conditions that do not use the composition of the present invention, and cells are difficult to exhibit uniform morphology, whereas under conditions using the composition of the present invention, the composition suppresses unnecessary differentiation. It is possible to maintain stable and effective dedifferentiated stem cells.
- the medium for culturing stem cells of the present invention can be used without limitation a basic medium known in the art.
- the basal medium may be prepared by artificially synthesizing, or a commercially prepared medium may be used. Examples of commercially prepared media include Dulbecco's Modified Eagle's Medium (DMEM), Minimal Essential Medium (MEM), Basic Medium Eagle (BME), RPMI 1640, F-10, F-12, ⁇ -MEM ( ⁇ -Minimal). essential medium), G-MEM (Glasgow's Minimal Essential Medium), and Isocove's Modified Dulbecco's Medium, but are not limited thereto.
- the basal medium preferably contains 10% (v / v) horse serum, in a specific embodiment of the present invention was cultured in DMEM medium.
- the present invention can provide a method for producing dedifferentiated stem cells having properties similar to embryonic stem cells in proliferative capacity and differentiation capacity using a composition containing a small molecule compound.
- the present invention relates to a method for maintaining stability and culturing of chromosomes of dedifferentiated stem cells using a composition comprising a small molecule compound. More specifically, the present invention relates to a new use of the composition comprising a small molecule compound as an active ingredient to improve the production efficiency of dedifferentiated stem cells, four reversed to the tail tip fibroblast extracted from the tail of the mouse Induction of differentiation factors (Oct4, Sox2, Klf4, c-Myc), followed by the induction of differentiation stem cell lines in medium and conditions containing small molecule compounds (ROCK inhibitor, MEK inhibitor, ALK5 inhibitor, antioxidant) as an active ingredient Not only can it be produced efficiently, it can also inhibit chromosomal mutations and DNA damage.
- ROCK inhibitor small molecule compounds
- results can be very useful for the manufacture of safe dedifferentiated stem cells that can be used for future clinical applications and the development of cell therapies for the treatment of various diseases after differentiation into various functional cells using the same. That is, the present invention can be usefully used as a source technology for the development of stem cell lines for cell therapy that can treat various refractory diseases.
- the present invention utilizes a known technique as a composition capable of maintaining pluripotency and inhibiting chromosomal mutation or DNA damage using a composition containing a small molecule compound as an active ingredient. It will be apparent to those skilled in the art to which the present invention pertains.
- Addgene's pMXs vector plasmid was purchased and used to produce retroviruses capable of delivering four types of retrograde factors Oct4, Klf4, Sox2, and cMyc.
- 293GPG cells a retrovirus production cell line, were grown to a density of about 80% in a 100 mm cell culture dish, and the corresponding plasmid was introduced into 293GPG cells by referring to the enclosed instructions using Lipofectamin 2000 product of Invitrogen. After 48 hours, the retrovirus secreted into the supernatant of the cell culture solution was collected every 5 ml for 2 weeks and stored at -80 ° C. Retroviruses were mixed with medium containing 2-4 ⁇ g / ml polybrene and incubated with cells for 4-5 hours to infect cells and transfer the genes into cells.
- the cells were cultured by adding MEK inhibitor, ALK5 inhibitor, ROCK inhibitor, and antioxidant to the medium composition.
- the small molecule compound was used alone or in combination with the MEK inhibitor PD0325901, the ALK5 inhibitor SB431542, the ROCK inhibitor thiazovivin, and the antioxidant L-ascorbic acid.
- Each small molecule compound was used as a powder product from manufacturers such as stemgent, cayman, and sigma.
- MEK inhibitor PD0325901 dissolved the reagent powder at a concentration of 0.5 mM in Dimethyl sulfoxide (DMSO) and stored it at -20 ° C as a 1000-fold concentrate
- the ALK5 inhibitor SB431542 stored the reagent powder at a concentration of 2 mM in Dimethyl sulfoxide (DMSO). It was dissolved in and stored at a temperature of -20 °C as a 1000 times concentrated solution.
- the ROCK inhibitor Thiazovivin dissolved the reagent powder at a concentration of 0.5 mM in Dimethyl sulfoxide (DMSO) and stored it at -20 ° C as a 1000-fold concentrate.
- the antioxidant L-ascorbic acid was used to concentrate the reagent powder at a concentration of 200 mM in tertiary distilled water. It was dissolved and stored at -20 ° C as a 1000-fold concentrate. Each small molecule compound was used as an additive component of the culture medium during the production or maintenance of dedifferentiated stem cells. In this case, the final concentration of the small molecule compound contained in the culture solution was 0.5 ⁇ M for PD0325901, 2 ⁇ M for SB431542, 0.5 ⁇ M for Thiazovivin, and 200 ⁇ M for L-ascorbic acid.
- Retrodifferentiated stem cells were obtained by injecting retrodifferentiation factors using retrovirus into fibroblasts (mouse tip tip fibroblast) extracted from the mouse tail. Specifically, mouse fibroblasts of about 2-3 passages were cultured in 50,000 to 100,000 cells in a 100 mm cell culture dish, each containing four plasmids of four differentiation factors Oct4, Klf4, Sox2, and cMyc. Retroviruses were infected with MOI 2 or higher.
- the composition of the basal medium for mouse stem cell culture was 2 mM L-glutamine, 10 mM beta-mercaptoethanol, 0.1 mM MEM NEAA, 500 unit / ml ESGRO (LIF), and 10% horse serum in DMEM high glucose medium from GIBCO.
- the antibiotic Pen / strep was added.
- FIG. 1B After about one week of incubation, it was confirmed that the embryonic stem cell-like form of dedifferentiated stem cell colony was formed on the support cells (FIG. 1B), and the colony of the formed dedifferentiated stem cell had similar characteristics to the embryonic stem cell.
- AP staining was carried out to confirm whether the colony of the re-differentiated stem cells showing a positive reaction by staining red (Fig. 1b).
- AP staining was performed using an experimental kit of stemgent and attached instructions. It was also confirmed that the composition comprising the small molecule compound of the present invention improved the speed and efficiency of reverse differentiation (FIG. 1C).
- the resulting dedifferentiated stem cell colony was physically removed using a glass pipette and cultured on new support cells. Once these stem cells were stabilized, they could be cultured on a gelatin-coated culture plate without supporting cells.
- Example 3 Confirmation of Pluripotency of Reverse Differentiated Stem Cells Using RT-PCR and Immunofluorescence Staining-Verification of Produced Differentiated Stem Cells
- the reverse differentiated stem cells for RT-PCR were treated with 0.05% Trypsin-EDTA for 2-3 minutes, separated into single cells, and then extracted with RNA by transferring the precipitate into a 1.5ml tube using a centrifuge.
- Cell RNA was isolated using TRI reagent. 3 ⁇ g of RNA was converted into cDNA using reverse transcriptase and oligo (dT), and then amplified by PCR using respective primers using the cDNA, and the expression level of the gene was examined by electrophoresis. It was confirmed that all of the differentiated stem cell lines prepared by PCR express pluripotent genes such as Oct4, Klf4, Sox2, Nanog, Rex1 (FIG. 2A).
- EB induced embryonic body
- a method of floating culture in the LIF-free culture condition that suppresses the differentiation of the differentiated stem cells was used. Specifically, the cultured dedifferentiated stem cells were washed with PBS and treated with 0.05% Trypsin-EDTA for 2-3 minutes to separate them into single cells, followed by 2mM L-glutamine and 10mM beta-mer in DMEM high glucose medium of GIBCO. Captoethanol, 0.1mM MEM NEAA, 10% Fetal Bovine Serum (FBS) and antibiotics Pen / strep were added to the medium for 4 days using a culture plate for bacterial culture without cell adhesion. EB was secured.
- the EB thus secured was transferred to a culture plate for cell culture and cultured in an adhered state, and the ectoderm, endoderm, and mesoderm differentiated cells formed at this time were identified through immunofluorescence staining.
- immunofluorescence staining all of the prepared dedifferentiated stem cell lines were found to have normal differentiation ability and to be capable of all three ectoderm differentiation (FIG. 3A).
- teratoma generation using immunodeficient mice was used.
- a method of transplanting dedifferentiated stem cells under the immunodeficient SCID mouse (BALB / c nu) was used.
- the cultured dedifferentiated stem cells were washed with PBS, separated into single cells using Trypsin-EDTA, and 1,000,000 cells were diluted with 0.1 ml of culture solution and mixed evenly with 0.1 ml of BD Matrigel matrix. They were then implanted by subcutaneous injection into the flank of SCID mice between 5 and 10 weeks of age.
- mice were bred for 8 to 10 weeks to observe the formation of teratoma, and the resulting teratoma was extracted and histologic analysis using H & E staining was confirmed by microscopic differentiation.
- histological analysis of teratoma all dedifferentiated stem cell lines normally produced teratoma, and all structures corresponding to ectoderm, endoderm, and mesoderm were found inside the tumor (FIG. 3B).
- Example 5 Confirming the stable maintenance effect of the retrodifferentiated stem cells by the composition containing the small molecule compound
- Morphological analysis, proliferation rate analysis, gene expression level analysis were performed to confirm the effect of the composition containing the small molecule compound in the dedifferentiated stem cells prepared and cultured in Example 2.
- the dedifferentiated stem cells (miPSC (-)) without using the composition, and the dedifferentiated stem produced using the composition
- the cells (miPSC (+)) were compared with each other under and without support cells.
- the degree of proliferation of the retrodifferentiated stem cells not using the composition and the retrodifferentiated stem cells produced using the composition were compared.
- the same number of cells were incubated for the same time, and the number of cells measured was compared.
- the time required for one-time division was found to be shorter in the differentiated stem cells treated with the composition containing the small molecule compound. Almost similar results were obtained (FIG. 4B).
- Example 2 the expression of the pluripotent genes identified in Example 2 was quantitatively analyzed to determine the effect of the composition containing the small molecule compound on the expression level of the pluripotent genes in the maintenance of dedifferentiated stem cells.
- the back-differentiated stem cell line using the composition containing the small molecule compound was confirmed that the expression level of most pluripotent genes is slightly higher (Fig. 4c).
- Example 6 Confirmation of the effect of improving the differentiation capacity of the retrodifferentiated stem cells by the composition containing the small molecule compound
- the retrodifferentiated stem cells and compositions without using the composition
- the efficiency of trioderm differentiation, the size of the resulting teratoma, and the formation efficiency of EB were compared between the dedifferentiated stem cells prepared by using.
- teratomas generated from cell lines that did not use the composition containing the small molecule compound were small in size, whereas teratomas generated from the cell line using the composition were small. It was confirmed that the teratoma produced in the embryonic stem cells is similar in size and the composition of the present invention improves the differentiation capacity in vivo (Fig. 5c).
- the cell line without the composition was compared with the cell line prepared using the composition.
- structural and numerical mutations of chromosomes occurred in dedifferentiated stem cells that did not use the composition containing the small molecule compound, whereas chromosomal mutations did not occur in dedifferentiated stem cell lines using the composition.
- structural mutation of the chromosome did not occur but mutation in the chromosome number. was confirmed that occurred.
- composition containing the small molecule compound can suppress the mutation of the chromosome of the dedifferentiated stem cells, and occur in the stage of induction of dedifferentiation and early stage culture as well as the maintenance of the long-term cell after that. It was confirmed that the inhibitory effect is also effective for possible mutations (Figs. 6A to 6D).
- the incidence rate of ⁇ H2AX protein was analyzed between the cell line not using the composition and the cell line prepared using the composition.
- the composition of the present invention is characterized by showing a state of DNA similar to that of normal fibroblasts or normal embryonic stem cells before dedifferentiation. DNA damage can be suppressed to a level similar to normal cells (Fig. 7b).
- composition for maintaining the chromosome stability of the dedifferentiated stem cells comprising the small molecule compound according to the present invention increases the speed and efficiency of dedifferentiation when preparing the dedifferentiated stem cells, and has an excellent effect on inhibiting structural and numerical mutations or DNA damage of chromosomes. It is also very useful for the development of anti-differentiated stem cell therapy with excellent chromosome stability.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (12)
- ROCK(Rho-associated kinase) 억제제, MEK(mitogen-activated protein kinase) 억제제, ALK5(Activin Receptor-Like Kinase-5) 억제제 및 항산화제로 구성된 군으로부터 선택된 하나 이상의 소분자 화합물을 유효성분으로 함유하는 역분화 줄기세포의 염색체 안정성 유지용 조성물.
- 제1항에 있어서, 상기 ROCK(Rho-associated kinase) 억제제는 티아조비빈(Thiazovivin), Y-27632, 파수딜(HA-1077), 하이드록시파수딜(HA-1100), H-1152, 3-(4-피리딜)-1H-인돌, N-(4-피리딜)-N'-(2,4,6-트리클로로페닐)우레아, 아우로티오글루코즈 및 LY294002로 구성된 군으로부터 선택된 하나 이상인 것을 특징으로 하는 조성물.
- 제1항에 있어서, 상기 MEK(mitogen-activated protein kinase) 억제제는 PD0325901 또는 U0126(1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene)인 것을 특징으로 하는 조성물.
- 제1항에 있어서, 상기 ALK5(Activin Receptor-Like Kinase-5) 억제제는 A-83-01 또는 SB431542인 것을 특징으로 하는 조성물.
- 제1항에 있어서, 상기 항산화제는 L-아스코르브산, 비타민E, A, C, 옥소티아졸리딘(Oxothiazolidine), N-이세틸시스테인(N-acetylcysteine), TEMPO, SOD(superoxide dismutase), 글루타치온 과산화효소, 스캐빈저 산소, 과산화수소, 리포옥사이드 라디칼, 히드록시 라디칼, 금속결합단백질, 셀레늄, 환원형 글루타치온, 베타카로틴, 플라보노이드(flavonoids), 세사몰(Sesamol), 몰식자산 유도체(Gallic Acid), 아요완(Ajowan), 오리자놀(Oryzanol), 레스베라트롤, 카테킨, 레시틴(lecithin), 세파린(cephalin), sulfhydrls(SRH), 구연산, 아스코르빈산, 카탈라아제(catalase), BHA, BHT, PG, NDGA, 하이드로퀴닌(hydroquinone), 카테콜(catechol) 및 DPPD(N,Ndiphenyl-pp-phenylene-diamine)로 구성된 군으로부터 선택된 하나 이상인 것을 특징으로 하는 조성물.
- 제1항에 있어서, 상기 줄기세포는 Oct4, Klf4, Sox2 및 cMyc로 구성된 군으로부터 선택된 하나 이상의 유전자 도입에 의해 유도되는 만능성 역분화 줄기세포인 것을 특징으로 하는 조성물.
- 제1항에 있어서, 염색체의 구조적, 수적 돌연변이 억제 또는 DNA 손상 억제를 통하여 염색체 안정성을 유지시키는 것을 특징으로 하는 조성물.
- 제1항 내지 제7항 중 어느 한 항의 조성물로 역분화 줄기세포를 처리하는 것을 특징으로 하는 역분화 줄기세포의 염색체 안정성 유지 방법.
- 제8항에 있어서, 상기 조성물은 체세포의 역분화를 유도하는 단계에 첨가되는 것을 특징으로 하는 역분화 줄기세포의 염색체 안정성 유지 방법.
- 제8항에 있어서, 상기 조성물은 역분화 유도 후에 첨가되는 것을 특징으로 하는 역분화 줄기세포의 염색체 안정성 유지 방법.
- 제1항 내지 제7항 중 어느 한 항의 조성물 존재하에 역분화 줄기세포를 배양하는 것을 특징으로 하는 역분화 줄기세포의 배양방법.
- 제11항에 있어서, 무-지지세포(feeder cell-free) 조건하에서 배양하는 단계를 추가로 포함하는 역분화 줄기세포의 배양방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480052269.2A CN105579579B (zh) | 2013-07-27 | 2014-07-22 | 包含小分子化合物的用于维持多能干细胞染色体稳定性的组合物 |
JP2016531516A JP6595468B2 (ja) | 2013-07-27 | 2014-07-22 | 小分子化合物を含む多能性幹細胞の染色体安定性維持用組成物 |
EP14832827.1A EP3029138B1 (en) | 2013-07-27 | 2014-07-22 | Composition for maintaining chromosome stability of pluripotent stem cells, containing small-molecule compound |
US14/906,547 US9752127B2 (en) | 2013-07-27 | 2014-07-22 | Composition for maintaining chromosomal stability of pluripotent stem cells, containing small-molecule compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130089205 | 2013-07-27 | ||
KR10-2013-0089205 | 2013-07-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015016523A1 true WO2015016523A1 (ko) | 2015-02-05 |
Family
ID=52432004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/006642 WO2015016523A1 (ko) | 2013-07-27 | 2014-07-22 | 소분자 화합물을 포함하는 만능성 줄기세포의 염색체 안정성 유지용 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9752127B2 (ko) |
EP (1) | EP3029138B1 (ko) |
JP (1) | JP6595468B2 (ko) |
KR (1) | KR101655383B1 (ko) |
CN (1) | CN105579579B (ko) |
WO (1) | WO2015016523A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114939097A (zh) * | 2017-05-02 | 2022-08-26 | 田边刚士 | 医药品组合物及化妆品组合物 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190183563A1 (en) * | 2016-06-14 | 2019-06-20 | The Standard Co., Ltd. | Therapeutic device employing endoscope-interworking electrode |
CN108300686B (zh) * | 2017-01-13 | 2022-08-26 | 云南美颜美龄生物科技有限公司 | 用于预防、延缓或逆转细胞、组织、器官、机体衰老的小分子化合物/组合,产品及其用途 |
EP3808855A4 (en) * | 2018-06-18 | 2022-03-23 | Shimadzu Corporation | METHOD OF EVALUATION OF GENOMIC ABNORMALITIES IN CELLS |
CN115315507A (zh) * | 2020-03-30 | 2022-11-08 | 东方酵母工业株式会社 | 干细胞的染色体稳定剂 |
AU2021400952A1 (en) * | 2020-12-15 | 2023-06-29 | Life Technologies Corporation | Chemically defined serum albumin substitutes |
CN112881113B (zh) * | 2021-01-12 | 2023-06-16 | 武汉呵尔医疗科技发展有限公司 | 一种稳定的粘液处理剂 |
CN114736872A (zh) * | 2022-05-06 | 2022-07-12 | 中国科学院动物研究所 | 提高多能干细胞性能的组合物、方法及其应用 |
CN115363016B (zh) * | 2022-08-09 | 2023-07-18 | 广州明迅生物科技有限责任公司 | 细胞储存液及其应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100101764A (ko) | 2009-03-10 | 2010-09-20 | 건국대학교 산학협력단 | 역분화 만능 줄기세포의 증식능 및 분화능 개선용 조성물 |
KR20100124335A (ko) * | 2008-03-17 | 2010-11-26 | 더 스크립스 리서치 인스티튜트 | 유도 만능 줄기 세포 생성을 위한 화학적 및 유전적 조합 접근법 |
WO2011082038A2 (en) * | 2009-12-31 | 2011-07-07 | Fate Therapeutics, Inc. | Improved reprogramming compositions |
KR20110094348A (ko) | 2008-12-17 | 2011-08-23 | 더 스크립스 리서치 인스티튜트 | 줄기 세포의 생성 및 유지 |
KR20110124106A (ko) * | 2010-05-10 | 2011-11-16 | 고려대학교 산학협력단 | Shh, FGFR 티로신 키나아제 억제제, MEK 억제제와 GSK 억제제를 이용하여 체세포로부터 배아줄기세포 유사세포로의 역분화를 유도하는 조성물 및 이를 이용한 배아줄기세포 유사세포의 제조방법 |
WO2012087965A2 (en) * | 2010-12-22 | 2012-06-28 | Fate Therapauetics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of ipscs |
KR20120094488A (ko) | 2009-10-31 | 2012-08-24 | 뉴 월드 레보러토리즈 인코포레이티드. | 세포의 재프로그램화 방법 및 이의 용도 |
KR20120121084A (ko) | 2011-04-26 | 2012-11-05 | 차의과학대학교 산학협력단 | 인간 배아줄기세포 또는 역분화 만능줄기세포의 줄기세포성 유지용 배지 및 이를 이용한 배양방법 |
KR101211610B1 (ko) | 2010-05-10 | 2012-12-12 | 주식회사 스템폰즈 | Bmi1, MEK 억제제와 GSK 억제제를 이용하여 체세포로부터 배아줄기세포 유사세포로의 역분화를 유도하는 조성물 및 이를 이용한 배아줄기세포 유사세포의 제조방법 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9295697B2 (en) * | 2009-11-04 | 2016-03-29 | Cellular Dynamics International, Inc. | Episomal reprogramming with chemicals |
WO2011123572A1 (en) | 2010-03-31 | 2011-10-06 | The Scripps Research Institute | Reprogramming cells |
KR101861168B1 (ko) * | 2010-06-15 | 2018-05-31 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 작은 부피의 말초 혈액으로부터의 유도된 만능 줄기 세포의 생성 |
JP6043999B2 (ja) | 2010-08-05 | 2016-12-14 | ウィスコンシン アラムニ リサーチ ファンデーション | ヒト多能性細胞培養のための簡易基本培地 |
JP2012143229A (ja) * | 2010-12-24 | 2012-08-02 | Chiba Univ | 多能性幹細胞培養用組成物およびその用途 |
US9133266B2 (en) * | 2011-05-06 | 2015-09-15 | Wisconsin Alumni Research Foundation | Vitronectin-derived cell culture substrate and uses thereof |
US20130040302A1 (en) * | 2011-07-11 | 2013-02-14 | Thomas J. Burke | Methods for cell reprogramming and genome engineering |
-
2014
- 2014-07-21 KR KR1020140092074A patent/KR101655383B1/ko active IP Right Grant
- 2014-07-22 WO PCT/KR2014/006642 patent/WO2015016523A1/ko active Application Filing
- 2014-07-22 JP JP2016531516A patent/JP6595468B2/ja active Active
- 2014-07-22 US US14/906,547 patent/US9752127B2/en active Active
- 2014-07-22 EP EP14832827.1A patent/EP3029138B1/en active Active
- 2014-07-22 CN CN201480052269.2A patent/CN105579579B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100124335A (ko) * | 2008-03-17 | 2010-11-26 | 더 스크립스 리서치 인스티튜트 | 유도 만능 줄기 세포 생성을 위한 화학적 및 유전적 조합 접근법 |
KR20110094348A (ko) | 2008-12-17 | 2011-08-23 | 더 스크립스 리서치 인스티튜트 | 줄기 세포의 생성 및 유지 |
KR20100101764A (ko) | 2009-03-10 | 2010-09-20 | 건국대학교 산학협력단 | 역분화 만능 줄기세포의 증식능 및 분화능 개선용 조성물 |
KR20120094488A (ko) | 2009-10-31 | 2012-08-24 | 뉴 월드 레보러토리즈 인코포레이티드. | 세포의 재프로그램화 방법 및 이의 용도 |
WO2011082038A2 (en) * | 2009-12-31 | 2011-07-07 | Fate Therapeutics, Inc. | Improved reprogramming compositions |
KR20110124106A (ko) * | 2010-05-10 | 2011-11-16 | 고려대학교 산학협력단 | Shh, FGFR 티로신 키나아제 억제제, MEK 억제제와 GSK 억제제를 이용하여 체세포로부터 배아줄기세포 유사세포로의 역분화를 유도하는 조성물 및 이를 이용한 배아줄기세포 유사세포의 제조방법 |
KR101211624B1 (ko) | 2010-05-10 | 2012-12-12 | 주식회사 스템폰즈 | Shh, FGFR 티로신 키나아제 억제제, MEK 억제제와 GSK 억제제를 이용하여 체세포로부터 배아줄기세포 유사세포로의 역분화를 유도하는 조성물 및 이를 이용한 배아줄기세포 유사세포의 제조방법 |
KR101211610B1 (ko) | 2010-05-10 | 2012-12-12 | 주식회사 스템폰즈 | Bmi1, MEK 억제제와 GSK 억제제를 이용하여 체세포로부터 배아줄기세포 유사세포로의 역분화를 유도하는 조성물 및 이를 이용한 배아줄기세포 유사세포의 제조방법 |
WO2012087965A2 (en) * | 2010-12-22 | 2012-06-28 | Fate Therapauetics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of ipscs |
KR20120121084A (ko) | 2011-04-26 | 2012-11-05 | 차의과학대학교 산학협력단 | 인간 배아줄기세포 또는 역분화 만능줄기세포의 줄기세포성 유지용 배지 및 이를 이용한 배양방법 |
Non-Patent Citations (7)
Title |
---|
LI, W.; WEI, W.; ZHU, S.; ZHU, J.; SHI, Y.; LIN, T.; HAO, E.; HAYEK, A.; DENG, H.; DING, S.: "Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors", CELL STEM CELL, vol. 4, 2009, pages 16 - 19 |
LI, W.; ZHOU, H.; ABUJAROUR, R.; ZHU, S.; YOUNG JOO, J.; LIN, T.; HAO, E.; SCHOLER, H.R.; HAYEK, A.; DING, S.: "Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2", STEM CELLS, vol. 27, 2009, pages 2992 - 3000 |
LIN, T.; AMBASUDHAN, R.; YUAN, X.; LI, W.; HILCOVE, S.; ABUJAROUR, R.; LIN, X.; HAHM, H.S.; HAO, E.; HAYEK, A. ET AL.: "A chemical platform for improved induction of human iPSCs", NAT METHODS, vol. 6, 2009, pages 805 - 808 |
LUO, L. ET AL.: "Effects of antioxidants on the quality and genomic stability of induced pluripotent stem cells", SCIENTIFIC REPORTS, vol. 4, no. 3779, 21 January 2014 (2014-01-21), pages 1 - 7, XP055279121 * |
See also references of EP3029138A4 * |
YUAN, X.; WAN, H.; ZHAO, X.; ZHU, S.; ZHOU, Q.; DING, S.: "Combined Chemical Treatment Enables Oct4-Induced Reprogramming from Mouse Embryonic Fibroblasts", STEM CELLS, 2011 |
ZHU, S.; LI, W.; ZHOU, H.; WEI, W.; AMBASUDHAN, R.; LIN, T.; KIM, J.; ZHANG, K.; DING, S.: "Reprogramming of human primary somatic cells by OCT4 and chemical compounds", CELL STEM CELL, vol. 7, 2010, pages 651 - 655 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114939097A (zh) * | 2017-05-02 | 2022-08-26 | 田边刚士 | 医药品组合物及化妆品组合物 |
Also Published As
Publication number | Publication date |
---|---|
KR20150013034A (ko) | 2015-02-04 |
KR101655383B1 (ko) | 2016-09-08 |
CN105579579A (zh) | 2016-05-11 |
US9752127B2 (en) | 2017-09-05 |
CN105579579B (zh) | 2020-12-25 |
US20160160183A1 (en) | 2016-06-09 |
EP3029138A4 (en) | 2017-03-22 |
JP6595468B2 (ja) | 2019-10-23 |
EP3029138A1 (en) | 2016-06-08 |
EP3029138B1 (en) | 2021-09-08 |
JP2016525370A (ja) | 2016-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015016523A1 (ko) | 소분자 화합물을 포함하는 만능성 줄기세포의 염색체 안정성 유지용 조성물 | |
Liu et al. | Generation of endoderm‐derived human induced pluripotent stem cells from primary hepatocytes | |
US20240043811A1 (en) | Method of producing a mesodermal-lineage primitive streak cell | |
Yang et al. | Generation of melanocytes from induced pluripotent stem cells | |
Linta et al. | Rat embryonic fibroblasts improve reprogramming of human keratinocytes into induced pluripotent stem cells | |
CN105431522A (zh) | 内侧神经节隆起前体细胞的体外产生 | |
Chen et al. | Promotion of the induction of cell pluripotency through metabolic remodeling by thyroid hormone triiodothyronine-activated PI3K/AKT signal pathway | |
US20100285577A1 (en) | Isolation, Characterization and Propagation of Germline Stem Cells | |
Hu et al. | GSK 3 inhibitor‐BIO regulates proliferation of female germline stem cells from the postnatal mouse ovary | |
Ghasemi‐Dehkordi et al. | Comparison between the cultures of human induced pluripotent stem cells (hiPSCs) on feeder‐and serum‐free system (Matrigel matrix), MEF and HDF feeder cell lines | |
US20240182867A1 (en) | Chemical reprogramming of human somatic cells into pluripotent cells | |
Tian et al. | Reprogrammed mouse astrocytes retain a “memory” of tissue origin and possess more tendencies for neuronal differentiation than reprogrammed mouse embryonic fibroblasts | |
WO2012141471A2 (ko) | 역분화-증진제를 이용한 역분화 만능 줄기세포의 제조방법 | |
WO2011019957A1 (en) | Method for formation of induced pluripotent stem cells | |
WO2018221904A2 (ko) | 인간 성체 간세포 리프로그래밍 배지 조성물 | |
El Ayachi et al. | Human dental stem cell derived transgene‐free iPSCs generate functional neurons via embryoid body‐mediated and direct induction methods | |
Wang et al. | FoxO3a contributes to the reprogramming process and the differentiation of induced pluripotent stem cells | |
Philonenko et al. | Current progress and potential practical application for human pluripotent stem cells | |
WO2021002554A1 (ko) | Cp1p 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 줄기세포 증식 촉진용 조성물 | |
WO2021034168A1 (ko) | 줄기세포의 증식 및 전능성 증진용 조성물 | |
WO2019117454A1 (ko) | 세포 소기관 스트레스 조절 인자를 이용하는 고효율 세포전환용 배지 첨가제 | |
WO2015133879A1 (ko) | 체세포로부터 희소돌기아교 전구세포로의 직접교차분화 유도용 조성물 및 이의 이용 | |
WO2017176054A1 (ko) | 줄기세포 배양용 배지조성물 및 그를 이용한 줄기세포 배양방법 | |
WO2014119893A1 (ko) | 식물 줄기세포 또는 식물 역분화 줄기 세포의 추출물을 이용한 맞춤형 만능줄기세포의 유도 방법 및 상기 방법에 의해 제조된 만능줄기세포 | |
WO2023177181A1 (ko) | 돼지 만능성 줄기세포 배양용 배지 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480052269.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14832827 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14906547 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016531516 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014832827 Country of ref document: EP |